S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:FEMY

Femasys (FEMY) Stock Price, News & Analysis

$1.94
+0.06 (+3.19%)
(As of 03/18/2024 ET)
Today's Range
$1.88
$2.12
50-Day Range
$0.75
$2.22
52-Week Range
$0.25
$4.75
Volume
800,646 shs
Average Volume
665,870 shs
Market Capitalization
$42.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Femasys MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
363.9% Upside
$9.00 Price Target
Short Interest
Healthy
2.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of Femasys in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.93) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.58 out of 5 stars

Medical Sector

519th out of 947 stocks

Surgical & Medical Instruments Industry

59th out of 99 stocks

FEMY stock logo

About Femasys Stock (NASDAQ:FEMY)

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

FEMY Stock Price History

FEMY Stock News Headlines

The only AI company you should be looking at
This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Femasys Stock (NASDAQ:FEMY), Short Interest Report
Femasys Names New Chief Medical Officer
Femasys Inc. EU MDR Final Audit Successfully Completed
See More Headlines
Receive FEMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/18/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:FEMY
Fax
N/A
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$10.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+363.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-11,390,000.00
Net Margins
-1,164.78%
Pretax Margin
-1,164.23%

Debt

Sales & Book Value

Annual Sales
$1.21 million
Book Value
$1.29 per share

Miscellaneous

Free Float
18,102,000
Market Cap
$42.00 million
Optionable
Not Optionable
Beta
-2.95
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Kathy Lee-Sepsick (Age 56)
    Founder, President, CEO & Director
    Comp: $453.58k
  • Mr. Dov Elefant (Age 57)
    Chief Financial Officer
    Comp: $355.72k
  • Mr. Daniel Scott Currie (Age 60)
    COO, Senior VP & Secretary
    Comp: $352.55k
  • Ms. Mary An Merchant J.D.
    Ph.D., Vice President of Counsel & Intellectual Property
  • Dr. Jeffrey Marcus M.D.
    M.S., Chief Medical Advisor
  • Ms. Christine Thomas (Age 51)
    Senior VP of Regulatory & Clinical Affairs
  • Dr. James H. Liu M.D.
    Chief Medical Officer
  • Mr. Richard Spector
    Chief Commercial Officer

FEMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Femasys stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Femasys in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FEMY shares.
View FEMY analyst ratings
or view top-rated stocks.

What is Femasys' stock price target for 2024?

3 brokers have issued twelve-month target prices for Femasys' shares. Their FEMY share price targets range from $7.00 to $10.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 363.9% from the stock's current price.
View analysts price targets for FEMY
or view top-rated stocks among Wall Street analysts.

How have FEMY shares performed in 2024?

Femasys' stock was trading at $0.9750 at the start of the year. Since then, FEMY stock has increased by 99.0% and is now trading at $1.94.
View the best growth stocks for 2024 here
.

Are investors shorting Femasys?

Femasys saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 499,700 shares, an increase of 61.9% from the February 14th total of 308,600 shares. Based on an average trading volume of 588,200 shares, the days-to-cover ratio is presently 0.8 days. Approximately 2.5% of the company's shares are sold short.
View Femasys' Short Interest
.

When is Femasys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our FEMY earnings forecast
.

How were Femasys' earnings last quarter?

Femasys Inc. (NASDAQ:FEMY) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.04. The firm had revenue of $0.27 million for the quarter. Femasys had a negative net margin of 1,164.78% and a negative trailing twelve-month return on equity of 100.01%.

When did Femasys IPO?

(FEMY) raised $35 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 2,700,000 shares at $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO.

Who are Femasys' major shareholders?

Femasys' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.72%), Vanguard Group Inc. (0.72%) and Northern Trust Corp (0.36%).
View institutional ownership trends
.

How do I buy shares of Femasys?

Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FEMY) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners